Skip to content
Screener

Twist Bioscience Corporation TWST Reportable Segment — Interest Income

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — Interest Income
$2.5M+400%
Bicara Therapeutics logo
BCAXReportable Segment — Interest Income
$4.08M-18.6%
nCino, Inc. logo
NCNOReportable Segment — Interest Income
$366K-12.2%
DocuSign logo
DOCUReportable Segment — Interest Income
$8.73M-18.4%
UiPath logo
PATHReportable Segment — Interest Income
$10.4M-17.8%
YSS
YSSReportable Segment — Interest Income
$4.62M+754%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Stock-based compensation expense18,93620,32832,20932,319
Total costs and expenses$156,578$134,353$293,176$257,711
Loss from operations$(45,863)$(41,560)$(78,763)$(76,205)
Interest income$1,710$2,801$3,885$6,041
Other income (expense), net175(394)646(487)
Income (loss) before income taxes$(43,978)$(39,153)$(74,232)$(70,651)
Income tax expense(43)(175)(296)(271)
Net loss$(44,021)$(39,328)$(74,528)$(70,922)

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's reportable segment — interest income?
Twist Bioscience Corporation (TWST) reported reportable segment — interest income of $1.71M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — interest income changed year-over-year?
Twist Bioscience Corporation's reportable segment — interest income decreased by 39.0% year-over-year, from $2.8M to $1.71M.
What does reportable segment — interest income mean?
Reflects the income generated from cash balances, investments, or financing activities specifically allocated to the reportable segment. It indicates the segment's ability to earn returns on its liquid assets or capital reserves.

Ask your AI about Twist Bioscience Corporation's reportable segment — interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude